nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—ALB—Levothyroxine—hypothyroidism	0.0956	0.157	CbGbCtD
Erlotinib—ALB—Liothyronine—hypothyroidism	0.0956	0.157	CbGbCtD
Erlotinib—ALB—Liotrix—hypothyroidism	0.0933	0.153	CbGbCtD
Erlotinib—CYP2C8—Levothyroxine—hypothyroidism	0.0739	0.121	CbGbCtD
Erlotinib—CYP2C8—Liotrix—hypothyroidism	0.0721	0.118	CbGbCtD
Erlotinib—ABCB1—Liothyronine—hypothyroidism	0.05	0.0821	CbGbCtD
Erlotinib—ABCB1—Levothyroxine—hypothyroidism	0.05	0.0821	CbGbCtD
Erlotinib—ABCB1—Liotrix—hypothyroidism	0.0488	0.0801	CbGbCtD
Erlotinib—CYP3A4—Levothyroxine—hypothyroidism	0.03	0.0492	CbGbCtD
Erlotinib—LTK—tongue—hypothyroidism	0.00747	0.0367	CbGeAlD
Erlotinib—Intestinal perforation—Liotrix—hypothyroidism	0.00677	0.0496	CcSEcCtD
Erlotinib—UGT1A1—urine—hypothyroidism	0.00441	0.0217	CbGeAlD
Erlotinib—Acute coronary syndrome—Liothyronine—hypothyroidism	0.00408	0.0299	CcSEcCtD
Erlotinib—ULK3—tongue—hypothyroidism	0.00406	0.02	CbGeAlD
Erlotinib—Myocardial infarction—Liothyronine—hypothyroidism	0.00406	0.0298	CcSEcCtD
Erlotinib—Arrhythmia—Liothyronine—hypothyroidism	0.00332	0.0244	CcSEcCtD
Erlotinib—Tenderness—Liotrix—hypothyroidism	0.00306	0.0225	CcSEcCtD
Erlotinib—Cellulitis—Liotrix—hypothyroidism	0.00294	0.0216	CcSEcCtD
Erlotinib—HIPK4—gonad—hypothyroidism	0.00246	0.0121	CbGeAlD
Erlotinib—Dehydration—Dextrothyroxine—hypothyroidism	0.00245	0.018	CcSEcCtD
Erlotinib—Dehydration—Levothyroxine—hypothyroidism	0.00245	0.018	CcSEcCtD
Erlotinib—AURKC—heart—hypothyroidism	0.00245	0.012	CbGeAlD
Erlotinib—Sepsis—Liotrix—hypothyroidism	0.00232	0.017	CcSEcCtD
Erlotinib—Dysphagia—Levothyroxine—hypothyroidism	0.00228	0.0167	CcSEcCtD
Erlotinib—Dysphagia—Dextrothyroxine—hypothyroidism	0.00228	0.0167	CcSEcCtD
Erlotinib—JAK3—heart—hypothyroidism	0.00227	0.0111	CbGeAlD
Erlotinib—Renal failure acute—Liotrix—hypothyroidism	0.0021	0.0154	CcSEcCtD
Erlotinib—AURKC—gonad—hypothyroidism	0.0021	0.0103	CbGeAlD
Erlotinib—Body temperature increased—Liothyronine—hypothyroidism	0.00209	0.0153	CcSEcCtD
Erlotinib—TNK1—heart—hypothyroidism	0.00208	0.0102	CbGeAlD
Erlotinib—Weight decreased—Dextrothyroxine—hypothyroidism	0.00206	0.0151	CcSEcCtD
Erlotinib—Weight decreased—Levothyroxine—hypothyroidism	0.00206	0.0151	CcSEcCtD
Erlotinib—Renal impairment—Liotrix—hypothyroidism	0.00204	0.015	CcSEcCtD
Erlotinib—Acute coronary syndrome—Dextrothyroxine—hypothyroidism	0.002	0.0147	CcSEcCtD
Erlotinib—Acute coronary syndrome—Levothyroxine—hypothyroidism	0.002	0.0147	CcSEcCtD
Erlotinib—Myocardial infarction—Dextrothyroxine—hypothyroidism	0.00199	0.0146	CcSEcCtD
Erlotinib—Myocardial infarction—Levothyroxine—hypothyroidism	0.00199	0.0146	CcSEcCtD
Erlotinib—Cerebrovascular accident—Liotrix—hypothyroidism	0.00198	0.0145	CcSEcCtD
Erlotinib—CYP1A2—urine—hypothyroidism	0.00195	0.00959	CbGeAlD
Erlotinib—EPHA6—gonad—hypothyroidism	0.00194	0.00955	CbGeAlD
Erlotinib—AURKC—adrenal gland—hypothyroidism	0.00183	0.00898	CbGeAlD
Erlotinib—Dehydration—Liotrix—hypothyroidism	0.00181	0.0132	CcSEcCtD
Erlotinib—FLT3—heart—hypothyroidism	0.00179	0.00879	CbGeAlD
Erlotinib—HIPK4—testis—hypothyroidism	0.00177	0.00871	CbGeAlD
Erlotinib—Hypokalaemia—Liotrix—hypothyroidism	0.00177	0.013	CcSEcCtD
Erlotinib—AURKC—thyroid gland—hypothyroidism	0.00177	0.00867	CbGeAlD
Erlotinib—LTK—testis—hypothyroidism	0.00175	0.00861	CbGeAlD
Erlotinib—TNK1—pituitary gland—hypothyroidism	0.00174	0.00855	CbGeAlD
Erlotinib—ABL2—heart—hypothyroidism	0.00171	0.0084	CbGeAlD
Erlotinib—JAK3—adrenal gland—hypothyroidism	0.00169	0.00832	CbGeAlD
Erlotinib—JAK3—blood—hypothyroidism	0.00169	0.00832	CbGeAlD
Erlotinib—FLT3—cardiovascular system—hypothyroidism	0.00169	0.0083	CbGeAlD
Erlotinib—Dysphagia—Liotrix—hypothyroidism	0.00168	0.0123	CcSEcCtD
Erlotinib—PIP4K2C—adrenal cortex—hypothyroidism	0.00167	0.00821	CbGeAlD
Erlotinib—EGFR—heart—hypothyroidism	0.00167	0.00819	CbGeAlD
Erlotinib—NR1I2—liver—hypothyroidism	0.00166	0.00814	CbGeAlD
Erlotinib—JAK3—thyroid gland—hypothyroidism	0.00163	0.00803	CbGeAlD
Erlotinib—Arrhythmia—Levothyroxine—hypothyroidism	0.00163	0.012	CcSEcCtD
Erlotinib—Arrhythmia—Dextrothyroxine—hypothyroidism	0.00163	0.012	CcSEcCtD
Erlotinib—PIP4K2C—heart—hypothyroidism	0.00162	0.00794	CbGeAlD
Erlotinib—Alopecia—Levothyroxine—hypothyroidism	0.00161	0.0118	CcSEcCtD
Erlotinib—Alopecia—Dextrothyroxine—hypothyroidism	0.00161	0.0118	CcSEcCtD
Erlotinib—ULK3—adrenal cortex—hypothyroidism	0.0016	0.00784	CbGeAlD
Erlotinib—JAK3—female gonad—hypothyroidism	0.00158	0.00776	CbGeAlD
Erlotinib—TNK1—adrenal gland—hypothyroidism	0.00156	0.00764	CbGeAlD
Erlotinib—TNK1—blood—hypothyroidism	0.00156	0.00764	CbGeAlD
Erlotinib—ULK3—heart—hypothyroidism	0.00154	0.00758	CbGeAlD
Erlotinib—FLT3—gonad—hypothyroidism	0.00153	0.00753	CbGeAlD
Erlotinib—Weight decreased—Liotrix—hypothyroidism	0.00152	0.0111	CcSEcCtD
Erlotinib—AURKC—testis—hypothyroidism	0.00151	0.00743	CbGeAlD
Erlotinib—MKNK1—adrenal cortex—hypothyroidism	0.0015	0.00738	CbGeAlD
Erlotinib—TNK1—thyroid gland—hypothyroidism	0.0015	0.00737	CbGeAlD
Erlotinib—Acute coronary syndrome—Liotrix—hypothyroidism	0.00147	0.0108	CcSEcCtD
Erlotinib—Renal failure—Liotrix—hypothyroidism	0.00147	0.0108	CcSEcCtD
Erlotinib—Myocardial infarction—Liotrix—hypothyroidism	0.00147	0.0108	CcSEcCtD
Erlotinib—MKNK1—heart—hypothyroidism	0.00145	0.00714	CbGeAlD
Erlotinib—TNK1—female gonad—hypothyroidism	0.00145	0.00712	CbGeAlD
Erlotinib—ABL2—pituitary gland—hypothyroidism	0.00143	0.00701	CbGeAlD
Erlotinib—SLK—adrenal cortex—hypothyroidism	0.00142	0.00699	CbGeAlD
Erlotinib—CYP3A4—urine—hypothyroidism	0.00141	0.00694	CbGeAlD
Erlotinib—JAK3—testis—hypothyroidism	0.0014	0.00688	CbGeAlD
Erlotinib—EPHA6—testis—hypothyroidism	0.0014	0.00688	CbGeAlD
Erlotinib—CYP2D6—urine—hypothyroidism	0.00139	0.00683	CbGeAlD
Erlotinib—PIP4K2C—gonad—hypothyroidism	0.00139	0.0068	CbGeAlD
Erlotinib—SLK—heart—hypothyroidism	0.00138	0.00676	CbGeAlD
Erlotinib—MKNK1—cardiovascular system—hypothyroidism	0.00137	0.00674	CbGeAlD
Erlotinib—Arthralgia—Dextrothyroxine—hypothyroidism	0.00135	0.00992	CcSEcCtD
Erlotinib—Arthralgia—Levothyroxine—hypothyroidism	0.00135	0.00992	CcSEcCtD
Erlotinib—PIP4K2C—pituitary gland—hypothyroidism	0.00135	0.00664	CbGeAlD
Erlotinib—Anxiety—Dextrothyroxine—hypothyroidism	0.00135	0.00989	CcSEcCtD
Erlotinib—Anxiety—Levothyroxine—hypothyroidism	0.00135	0.00989	CcSEcCtD
Erlotinib—FLT3—adrenal gland—hypothyroidism	0.00134	0.00656	CbGeAlD
Erlotinib—FLT3—blood—hypothyroidism	0.00134	0.00656	CbGeAlD
Erlotinib—ULK3—gonad—hypothyroidism	0.00132	0.0065	CbGeAlD
Erlotinib—JAK3—cerebellum—hypothyroidism	0.00129	0.00636	CbGeAlD
Erlotinib—ULK3—pituitary gland—hypothyroidism	0.00129	0.00634	CbGeAlD
Erlotinib—TNK1—testis—hypothyroidism	0.00129	0.00632	CbGeAlD
Erlotinib—Shock—Levothyroxine—hypothyroidism	0.00128	0.00936	CcSEcCtD
Erlotinib—Shock—Dextrothyroxine—hypothyroidism	0.00128	0.00936	CcSEcCtD
Erlotinib—ABL2—adrenal gland—hypothyroidism	0.00128	0.00627	CbGeAlD
Erlotinib—ABL2—blood—hypothyroidism	0.00128	0.00627	CbGeAlD
Erlotinib—MAP3K19—testis—hypothyroidism	0.00127	0.00625	CbGeAlD
Erlotinib—FLT3—female gonad—hypothyroidism	0.00125	0.00612	CbGeAlD
Erlotinib—EGFR—adrenal gland—hypothyroidism	0.00125	0.00612	CbGeAlD
Erlotinib—MKNK1—gonad—hypothyroidism	0.00124	0.00611	CbGeAlD
Erlotinib—ABL2—thyroid gland—hypothyroidism	0.00123	0.00605	CbGeAlD
Erlotinib—TNK1—liver—hypothyroidism	0.00122	0.00597	CbGeAlD
Erlotinib—MKNK1—pituitary gland—hypothyroidism	0.00121	0.00596	CbGeAlD
Erlotinib—PIP4K2C—adrenal gland—hypothyroidism	0.00121	0.00593	CbGeAlD
Erlotinib—PIP4K2C—blood—hypothyroidism	0.00121	0.00593	CbGeAlD
Erlotinib—EGFR—thyroid gland—hypothyroidism	0.0012	0.0059	CbGeAlD
Erlotinib—Arrhythmia—Liotrix—hypothyroidism	0.0012	0.0088	CcSEcCtD
Erlotinib—STK10—heart—hypothyroidism	0.0012	0.00588	CbGeAlD
Erlotinib—ABL2—female gonad—hypothyroidism	0.00119	0.00584	CbGeAlD
Erlotinib—TNK1—cerebellum—hypothyroidism	0.00119	0.00583	CbGeAlD
Erlotinib—Alopecia—Liotrix—hypothyroidism	0.00119	0.0087	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Levothyroxine—hypothyroidism	0.00118	0.00867	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Dextrothyroxine—hypothyroidism	0.00118	0.00867	CcSEcCtD
Erlotinib—Insomnia—Levothyroxine—hypothyroidism	0.00117	0.0086	CcSEcCtD
Erlotinib—Insomnia—Dextrothyroxine—hypothyroidism	0.00117	0.0086	CcSEcCtD
Erlotinib—PIP4K2C—thyroid gland—hypothyroidism	0.00116	0.00572	CbGeAlD
Erlotinib—EGFR—female gonad—hypothyroidism	0.00116	0.0057	CbGeAlD
Erlotinib—Dyspnoea—Dextrothyroxine—hypothyroidism	0.00116	0.00848	CcSEcCtD
Erlotinib—Dyspnoea—Levothyroxine—hypothyroidism	0.00116	0.00848	CcSEcCtD
Erlotinib—ULK3—adrenal gland—hypothyroidism	0.00115	0.00566	CbGeAlD
Erlotinib—ULK3—blood—hypothyroidism	0.00115	0.00566	CbGeAlD
Erlotinib—Flatulence—Liotrix—hypothyroidism	0.00115	0.00845	CcSEcCtD
Erlotinib—SLK—pituitary gland—hypothyroidism	0.00115	0.00565	CbGeAlD
Erlotinib—STK10—cardiovascular system—hypothyroidism	0.00113	0.00555	CbGeAlD
Erlotinib—PIP4K2C—female gonad—hypothyroidism	0.00113	0.00553	CbGeAlD
Erlotinib—Fatigue—Dextrothyroxine—hypothyroidism	0.00112	0.0082	CcSEcCtD
Erlotinib—Fatigue—Levothyroxine—hypothyroidism	0.00112	0.0082	CcSEcCtD
Erlotinib—ULK3—thyroid gland—hypothyroidism	0.00111	0.00546	CbGeAlD
Erlotinib—MAP2K5—adrenal cortex—hypothyroidism	0.00111	0.00543	CbGeAlD
Erlotinib—FLT3—testis—hypothyroidism	0.00111	0.00543	CbGeAlD
Erlotinib—MKNK1—adrenal gland—hypothyroidism	0.00108	0.00533	CbGeAlD
Erlotinib—MKNK1—blood—hypothyroidism	0.00108	0.00533	CbGeAlD
Erlotinib—ULK3—female gonad—hypothyroidism	0.00107	0.00528	CbGeAlD
Erlotinib—MAP2K5—heart—hypothyroidism	0.00107	0.00525	CbGeAlD
Erlotinib—Gastrointestinal pain—Levothyroxine—hypothyroidism	0.00106	0.00778	CcSEcCtD
Erlotinib—Gastrointestinal pain—Dextrothyroxine—hypothyroidism	0.00106	0.00778	CcSEcCtD
Erlotinib—ABL2—testis—hypothyroidism	0.00106	0.00518	CbGeAlD
Erlotinib—Syncope—Liotrix—hypothyroidism	0.00105	0.00769	CcSEcCtD
Erlotinib—MKNK1—thyroid gland—hypothyroidism	0.00105	0.00514	CbGeAlD
Erlotinib—FLT3—liver—hypothyroidism	0.00104	0.00513	CbGeAlD
Erlotinib—EGFR—testis—hypothyroidism	0.00103	0.00506	CbGeAlD
Erlotinib—SLK—adrenal gland—hypothyroidism	0.00103	0.00505	CbGeAlD
Erlotinib—Loss of consciousness—Liotrix—hypothyroidism	0.00103	0.00754	CcSEcCtD
Erlotinib—SLK—blood—hypothyroidism	0.00103	0.00504	CbGeAlD
Erlotinib—Body temperature increased—Levothyroxine—hypothyroidism	0.00103	0.00752	CcSEcCtD
Erlotinib—Abdominal pain—Levothyroxine—hypothyroidism	0.00103	0.00752	CcSEcCtD
Erlotinib—Body temperature increased—Dextrothyroxine—hypothyroidism	0.00103	0.00752	CcSEcCtD
Erlotinib—Abdominal pain—Dextrothyroxine—hypothyroidism	0.00103	0.00752	CcSEcCtD
Erlotinib—STK10—gonad—hypothyroidism	0.00103	0.00503	CbGeAlD
Erlotinib—FLT3—cerebellum—hypothyroidism	0.00102	0.00501	CbGeAlD
Erlotinib—MKNK1—female gonad—hypothyroidism	0.00101	0.00497	CbGeAlD
Erlotinib—MAP2K5—cardiovascular system—hypothyroidism	0.00101	0.00495	CbGeAlD
Erlotinib—PIP4K2C—testis—hypothyroidism	0.000998	0.0049	CbGeAlD
Erlotinib—ABL2—liver—hypothyroidism	0.000998	0.0049	CbGeAlD
Erlotinib—Chest pain—Liotrix—hypothyroidism	0.000995	0.0073	CcSEcCtD
Erlotinib—Arthralgia—Liotrix—hypothyroidism	0.000995	0.0073	CcSEcCtD
Erlotinib—Anxiety—Liotrix—hypothyroidism	0.000992	0.00727	CcSEcCtD
Erlotinib—SLK—thyroid gland—hypothyroidism	0.000991	0.00487	CbGeAlD
Erlotinib—ABL2—cerebellum—hypothyroidism	0.000975	0.00479	CbGeAlD
Erlotinib—EGFR—liver—hypothyroidism	0.000974	0.00478	CbGeAlD
Erlotinib—SLK—female gonad—hypothyroidism	0.000958	0.0047	CbGeAlD
Erlotinib—Oedema—Liotrix—hypothyroidism	0.000954	0.007	CcSEcCtD
Erlotinib—ULK3—testis—hypothyroidism	0.000953	0.00468	CbGeAlD
Erlotinib—EGFR—cerebellum—hypothyroidism	0.000951	0.00467	CbGeAlD
Erlotinib—Infection—Liotrix—hypothyroidism	0.000948	0.00695	CcSEcCtD
Erlotinib—PIP4K2C—liver—hypothyroidism	0.000944	0.00464	CbGeAlD
Erlotinib—Shock—Liotrix—hypothyroidism	0.000939	0.00688	CcSEcCtD
Erlotinib—Asthenia—Dextrothyroxine—hypothyroidism	0.000931	0.00683	CcSEcCtD
Erlotinib—Asthenia—Levothyroxine—hypothyroidism	0.000931	0.00683	CcSEcCtD
Erlotinib—PIP4K2C—cerebellum—hypothyroidism	0.000922	0.00453	CbGeAlD
Erlotinib—Pruritus—Levothyroxine—hypothyroidism	0.000918	0.00673	CcSEcCtD
Erlotinib—Pruritus—Dextrothyroxine—hypothyroidism	0.000918	0.00673	CcSEcCtD
Erlotinib—Anorexia—Liotrix—hypothyroidism	0.000909	0.00667	CcSEcCtD
Erlotinib—ULK3—liver—hypothyroidism	0.000901	0.00443	CbGeAlD
Erlotinib—MKNK1—testis—hypothyroidism	0.000897	0.00441	CbGeAlD
Erlotinib—STK10—adrenal gland—hypothyroidism	0.000893	0.00439	CbGeAlD
Erlotinib—STK10—blood—hypothyroidism	0.000893	0.00439	CbGeAlD
Erlotinib—MAP2K5—pituitary gland—hypothyroidism	0.000893	0.00439	CbGeAlD
Erlotinib—Diarrhoea—Dextrothyroxine—hypothyroidism	0.000887	0.00651	CcSEcCtD
Erlotinib—Diarrhoea—Levothyroxine—hypothyroidism	0.000887	0.00651	CcSEcCtD
Erlotinib—ULK3—cerebellum—hypothyroidism	0.00088	0.00432	CbGeAlD
Erlotinib—Musculoskeletal discomfort—Liotrix—hypothyroidism	0.000869	0.00638	CcSEcCtD
Erlotinib—Insomnia—Liotrix—hypothyroidism	0.000863	0.00633	CcSEcCtD
Erlotinib—STK10—thyroid gland—hypothyroidism	0.000862	0.00423	CbGeAlD
Erlotinib—ABL1—adrenal cortex—hypothyroidism	0.000853	0.00419	CbGeAlD
Erlotinib—Dyspnoea—Liotrix—hypothyroidism	0.000851	0.00624	CcSEcCtD
Erlotinib—SLK—testis—hypothyroidism	0.00085	0.00417	CbGeAlD
Erlotinib—MKNK1—liver—hypothyroidism	0.000848	0.00417	CbGeAlD
Erlotinib—UGT1A1—blood—hypothyroidism	0.000844	0.00414	CbGeAlD
Erlotinib—STK10—female gonad—hypothyroidism	0.000833	0.00409	CbGeAlD
Erlotinib—SLCO2B1—heart—hypothyroidism	0.000832	0.00409	CbGeAlD
Erlotinib—Decreased appetite—Liotrix—hypothyroidism	0.000829	0.00608	CcSEcCtD
Erlotinib—MKNK1—cerebellum—hypothyroidism	0.000829	0.00407	CbGeAlD
Erlotinib—ABL1—heart—hypothyroidism	0.000825	0.00405	CbGeAlD
Erlotinib—Vomiting—Dextrothyroxine—hypothyroidism	0.000825	0.00605	CcSEcCtD
Erlotinib—Vomiting—Levothyroxine—hypothyroidism	0.000825	0.00605	CcSEcCtD
Erlotinib—Fatigue—Liotrix—hypothyroidism	0.000823	0.00603	CcSEcCtD
Erlotinib—Rash—Levothyroxine—hypothyroidism	0.000818	0.006	CcSEcCtD
Erlotinib—Rash—Dextrothyroxine—hypothyroidism	0.000818	0.006	CcSEcCtD
Erlotinib—Dermatitis—Dextrothyroxine—hypothyroidism	0.000817	0.00599	CcSEcCtD
Erlotinib—Dermatitis—Levothyroxine—hypothyroidism	0.000817	0.00599	CcSEcCtD
Erlotinib—Constipation—Liotrix—hypothyroidism	0.000816	0.00598	CcSEcCtD
Erlotinib—Headache—Levothyroxine—hypothyroidism	0.000813	0.00596	CcSEcCtD
Erlotinib—Headache—Dextrothyroxine—hypothyroidism	0.000813	0.00596	CcSEcCtD
Erlotinib—SLK—liver—hypothyroidism	0.000803	0.00395	CbGeAlD
Erlotinib—MAP2K5—adrenal gland—hypothyroidism	0.000798	0.00392	CbGeAlD
Erlotinib—MAP2K5—blood—hypothyroidism	0.000798	0.00392	CbGeAlD
Erlotinib—SLK—cerebellum—hypothyroidism	0.000785	0.00385	CbGeAlD
Erlotinib—Gastrointestinal pain—Liotrix—hypothyroidism	0.00078	0.00572	CcSEcCtD
Erlotinib—ABL1—cardiovascular system—hypothyroidism	0.000778	0.00382	CbGeAlD
Erlotinib—Nausea—Dextrothyroxine—hypothyroidism	0.00077	0.00565	CcSEcCtD
Erlotinib—Nausea—Levothyroxine—hypothyroidism	0.00077	0.00565	CcSEcCtD
Erlotinib—MAP2K5—thyroid gland—hypothyroidism	0.00077	0.00378	CbGeAlD
Erlotinib—ALB—heart—hypothyroidism	0.000761	0.00374	CbGeAlD
Erlotinib—Abdominal pain—Liotrix—hypothyroidism	0.000754	0.00553	CcSEcCtD
Erlotinib—Body temperature increased—Liotrix—hypothyroidism	0.000754	0.00553	CcSEcCtD
Erlotinib—MAP2K5—female gonad—hypothyroidism	0.000744	0.00365	CbGeAlD
Erlotinib—STK10—testis—hypothyroidism	0.000739	0.00363	CbGeAlD
Erlotinib—ABL1—gonad—hypothyroidism	0.000706	0.00347	CbGeAlD
Erlotinib—STK10—liver—hypothyroidism	0.000699	0.00343	CbGeAlD
Erlotinib—CYP1B1—heart—hypothyroidism	0.000698	0.00343	CbGeAlD
Erlotinib—ABL1—pituitary gland—hypothyroidism	0.000689	0.00338	CbGeAlD
Erlotinib—Asthenia—Liotrix—hypothyroidism	0.000684	0.00502	CcSEcCtD
Erlotinib—STK10—cerebellum—hypothyroidism	0.000682	0.00335	CbGeAlD
Erlotinib—Pruritus—Liotrix—hypothyroidism	0.000675	0.00495	CcSEcCtD
Erlotinib—MAP2K5—testis—hypothyroidism	0.00066	0.00324	CbGeAlD
Erlotinib—UGT1A1—liver—hypothyroidism	0.00066	0.00324	CbGeAlD
Erlotinib—CYP1B1—cardiovascular system—hypothyroidism	0.000659	0.00324	CbGeAlD
Erlotinib—Diarrhoea—Liotrix—hypothyroidism	0.000653	0.00479	CcSEcCtD
Erlotinib—ORM1—blood—hypothyroidism	0.000648	0.00318	CbGeAlD
Erlotinib—Dizziness—Liotrix—hypothyroidism	0.000631	0.00463	CcSEcCtD
Erlotinib—MAP2K5—liver—hypothyroidism	0.000624	0.00306	CbGeAlD
Erlotinib—SLCO2B1—adrenal gland—hypothyroidism	0.000621	0.00305	CbGeAlD
Erlotinib—ABL1—adrenal gland—hypothyroidism	0.000616	0.00302	CbGeAlD
Erlotinib—ABL1—blood—hypothyroidism	0.000615	0.00302	CbGeAlD
Erlotinib—MAP2K5—cerebellum—hypothyroidism	0.000609	0.00299	CbGeAlD
Erlotinib—Vomiting—Liotrix—hypothyroidism	0.000607	0.00445	CcSEcCtD
Erlotinib—Rash—Liotrix—hypothyroidism	0.000602	0.00441	CcSEcCtD
Erlotinib—Dermatitis—Liotrix—hypothyroidism	0.000601	0.00441	CcSEcCtD
Erlotinib—SLCO2B1—thyroid gland—hypothyroidism	0.000599	0.00294	CbGeAlD
Erlotinib—CYP1B1—gonad—hypothyroidism	0.000598	0.00294	CbGeAlD
Erlotinib—Headache—Liotrix—hypothyroidism	0.000598	0.00438	CcSEcCtD
Erlotinib—ABL1—thyroid gland—hypothyroidism	0.000594	0.00292	CbGeAlD
Erlotinib—CYP1B1—pituitary gland—hypothyroidism	0.000584	0.00287	CbGeAlD
Erlotinib—SLCO2B1—female gonad—hypothyroidism	0.000579	0.00284	CbGeAlD
Erlotinib—ABL1—female gonad—hypothyroidism	0.000574	0.00282	CbGeAlD
Erlotinib—ALB—adrenal gland—hypothyroidism	0.000568	0.00279	CbGeAlD
Erlotinib—Nausea—Liotrix—hypothyroidism	0.000567	0.00416	CcSEcCtD
Erlotinib—ABCG2—adrenal cortex—hypothyroidism	0.000538	0.00264	CbGeAlD
Erlotinib—CYP1B1—adrenal gland—hypothyroidism	0.000521	0.00256	CbGeAlD
Erlotinib—CYP1B1—blood—hypothyroidism	0.000521	0.00256	CbGeAlD
Erlotinib—ABCG2—heart—hypothyroidism	0.00052	0.00255	CbGeAlD
Erlotinib—SLCO2B1—testis—hypothyroidism	0.000513	0.00252	CbGeAlD
Erlotinib—ABL1—testis—hypothyroidism	0.000509	0.0025	CbGeAlD
Erlotinib—ORM1—liver—hypothyroidism	0.000506	0.00249	CbGeAlD
Erlotinib—CYP1B1—thyroid gland—hypothyroidism	0.000503	0.00247	CbGeAlD
Erlotinib—CYP1A1—heart—hypothyroidism	0.000494	0.00242	CbGeAlD
Erlotinib—CYP1B1—female gonad—hypothyroidism	0.000486	0.00239	CbGeAlD
Erlotinib—SLCO2B1—liver—hypothyroidism	0.000485	0.00238	CbGeAlD
Erlotinib—ABL1—liver—hypothyroidism	0.000481	0.00236	CbGeAlD
Erlotinib—SLCO2B1—cerebellum—hypothyroidism	0.000474	0.00233	CbGeAlD
Erlotinib—ABL1—cerebellum—hypothyroidism	0.00047	0.00231	CbGeAlD
Erlotinib—ALB—testis—hypothyroidism	0.00047	0.00231	CbGeAlD
Erlotinib—CYP2C8—pituitary gland—hypothyroidism	0.000447	0.00219	CbGeAlD
Erlotinib—ALB—liver—hypothyroidism	0.000444	0.00218	CbGeAlD
Erlotinib—ABCG2—pituitary gland—hypothyroidism	0.000434	0.00213	CbGeAlD
Erlotinib—CYP1B1—testis—hypothyroidism	0.000431	0.00212	CbGeAlD
Erlotinib—CYP1B1—liver—hypothyroidism	0.000408	0.002	CbGeAlD
Erlotinib—CYP2C8—blood—hypothyroidism	0.000399	0.00196	CbGeAlD
Erlotinib—CYP1B1—cerebellum—hypothyroidism	0.000398	0.00196	CbGeAlD
Erlotinib—ABCG2—adrenal gland—hypothyroidism	0.000388	0.00191	CbGeAlD
Erlotinib—ABCG2—blood—hypothyroidism	0.000388	0.00191	CbGeAlD
Erlotinib—ABCG2—thyroid gland—hypothyroidism	0.000375	0.00184	CbGeAlD
Erlotinib—CYP1A2—blood—hypothyroidism	0.000373	0.00183	CbGeAlD
Erlotinib—CYP1A1—blood—hypothyroidism	0.000368	0.00181	CbGeAlD
Erlotinib—ABCG2—female gonad—hypothyroidism	0.000362	0.00178	CbGeAlD
Erlotinib—CYP1A2—thyroid gland—hypothyroidism	0.00036	0.00177	CbGeAlD
Erlotinib—CYP3A5—blood—hypothyroidism	0.00036	0.00177	CbGeAlD
Erlotinib—CYP1A1—thyroid gland—hypothyroidism	0.000356	0.00175	CbGeAlD
Erlotinib—CYP1A1—female gonad—hypothyroidism	0.000344	0.00169	CbGeAlD
Erlotinib—CYP3A5—female gonad—hypothyroidism	0.000336	0.00165	CbGeAlD
Erlotinib—CYP2C8—testis—hypothyroidism	0.00033	0.00162	CbGeAlD
Erlotinib—ABCG2—testis—hypothyroidism	0.000321	0.00158	CbGeAlD
Erlotinib—CYP2C8—liver—hypothyroidism	0.000312	0.00153	CbGeAlD
Erlotinib—ABCG2—liver—hypothyroidism	0.000303	0.00149	CbGeAlD
Erlotinib—ABCG2—cerebellum—hypothyroidism	0.000296	0.00146	CbGeAlD
Erlotinib—CYP1A2—liver—hypothyroidism	0.000292	0.00143	CbGeAlD
Erlotinib—CYP1A1—liver—hypothyroidism	0.000288	0.00141	CbGeAlD
Erlotinib—CYP3A5—liver—hypothyroidism	0.000282	0.00138	CbGeAlD
Erlotinib—CYP3A4—blood—hypothyroidism	0.00027	0.00133	CbGeAlD
Erlotinib—CYP2D6—blood—hypothyroidism	0.000266	0.00131	CbGeAlD
Erlotinib—ABCB1—adrenal cortex—hypothyroidism	0.000265	0.0013	CbGeAlD
Erlotinib—ABCB1—heart—hypothyroidism	0.000256	0.00126	CbGeAlD
Erlotinib—CYP2D6—female gonad—hypothyroidism	0.000248	0.00122	CbGeAlD
Erlotinib—ABCB1—cardiovascular system—hypothyroidism	0.000242	0.00119	CbGeAlD
Erlotinib—CYP2D6—testis—hypothyroidism	0.00022	0.00108	CbGeAlD
Erlotinib—ABCB1—gonad—hypothyroidism	0.00022	0.00108	CbGeAlD
Erlotinib—ABCB1—pituitary gland—hypothyroidism	0.000214	0.00105	CbGeAlD
Erlotinib—CYP3A4—liver—hypothyroidism	0.000211	0.00104	CbGeAlD
Erlotinib—ALB—Transport of vitamins, nucleosides, and related molecules—AVP—hypothyroidism	0.00021	0.00412	CbGpPWpGaD
Erlotinib—CYP2D6—liver—hypothyroidism	0.000208	0.00102	CbGeAlD
Erlotinib—CYP2D6—cerebellum—hypothyroidism	0.000203	0.000998	CbGeAlD
Erlotinib—SLCO2B1—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	0.000201	0.00394	CbGpPWpGaD
Erlotinib—EGFR—Signaling by SCF-KIT—SH2B3—hypothyroidism	0.000193	0.00379	CbGpPWpGaD
Erlotinib—ABCB1—adrenal gland—hypothyroidism	0.000191	0.00094	CbGeAlD
Erlotinib—ABCB1—blood—hypothyroidism	0.000191	0.00094	CbGeAlD
Erlotinib—SLCO2B1—SLC-mediated transmembrane transport—SLC5A5—hypothyroidism	0.000191	0.00374	CbGpPWpGaD
Erlotinib—EPHA6—Axon guidance—VAV3—hypothyroidism	0.00019	0.00373	CbGpPWpGaD
Erlotinib—JAK3—Cytokine Signaling in Immune system—PRL—hypothyroidism	0.000189	0.00371	CbGpPWpGaD
Erlotinib—ABCB1—thyroid gland—hypothyroidism	0.000185	0.000907	CbGeAlD
Erlotinib—EGFR—Regulation of Actin Cytoskeleton—PIK3C2A—hypothyroidism	0.000184	0.00362	CbGpPWpGaD
Erlotinib—NR1I2—Gene Expression—NKX2-5—hypothyroidism	0.000179	0.00351	CbGpPWpGaD
Erlotinib—ABCB1—female gonad—hypothyroidism	0.000178	0.000876	CbGeAlD
Erlotinib—UGT1A1—NRF2 pathway—SLC5A5—hypothyroidism	0.000173	0.0034	CbGpPWpGaD
Erlotinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—TRH—hypothyroidism	0.000173	0.0034	CbGpPWpGaD
Erlotinib—CYP1B1—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	0.000172	0.00338	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—CLTC—hypothyroidism	0.000169	0.00332	CbGpPWpGaD
Erlotinib—EGFR—SHP2 signaling—IGF1—hypothyroidism	0.000166	0.00326	CbGpPWpGaD
Erlotinib—NR1I2—Gene Expression—THRB—hypothyroidism	0.000161	0.00317	CbGpPWpGaD
Erlotinib—ABL2—Developmental Biology—VAV3—hypothyroidism	0.000161	0.00316	CbGpPWpGaD
Erlotinib—JAK3—Hemostasis—SH2B3—hypothyroidism	0.000159	0.00311	CbGpPWpGaD
Erlotinib—ABCB1—testis—hypothyroidism	0.000158	0.000777	CbGeAlD
Erlotinib—SLCO2B1—SLC-mediated transmembrane transport—AVP—hypothyroidism	0.00015	0.00295	CbGpPWpGaD
Erlotinib—ABCB1—liver—hypothyroidism	0.00015	0.000735	CbGeAlD
Erlotinib—ABCB1—cerebellum—hypothyroidism	0.000146	0.000718	CbGeAlD
Erlotinib—EGFR—Axon guidance—CLTC—hypothyroidism	0.000144	0.00283	CbGpPWpGaD
Erlotinib—ALB—SLC-mediated transmembrane transport—SLC5A7—hypothyroidism	0.000143	0.00281	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling by NGF—VAV3—hypothyroidism	0.00014	0.00275	CbGpPWpGaD
Erlotinib—CYP1B1—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.00014	0.00274	CbGpPWpGaD
Erlotinib—ABL1—EGF/EGFR Signaling Pathway—VAV3—hypothyroidism	0.000139	0.00272	CbGpPWpGaD
Erlotinib—EPHA6—Developmental Biology—VAV3—hypothyroidism	0.000136	0.00266	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB4—PRL—hypothyroidism	0.000135	0.00264	CbGpPWpGaD
Erlotinib—JAK3—Platelet activation, signaling and aggregation—IGF1—hypothyroidism	0.00013	0.00255	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—TRH—hypothyroidism	0.000126	0.00248	CbGpPWpGaD
Erlotinib—JAK3—Immune System—CLTC—hypothyroidism	0.000121	0.00238	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—CLTC—hypothyroidism	0.00012	0.00237	CbGpPWpGaD
Erlotinib—MAP2K5—Focal Adhesion—IGF1—hypothyroidism	0.00012	0.00235	CbGpPWpGaD
Erlotinib—ALB—SLC-mediated transmembrane transport—SLC26A4—hypothyroidism	0.000118	0.00233	CbGpPWpGaD
Erlotinib—EGFR—EGF/EGFR Signaling Pathway—VAV3—hypothyroidism	0.000118	0.00232	CbGpPWpGaD
Erlotinib—ABCG2—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	0.000118	0.00231	CbGpPWpGaD
Erlotinib—EGFR—DAP12 signaling—VAV3—hypothyroidism	0.000117	0.0023	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—TRH—hypothyroidism	0.000115	0.00225	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—TSHB—hypothyroidism	0.000112	0.00221	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—TSHR—hypothyroidism	0.000112	0.00221	CbGpPWpGaD
Erlotinib—CYP3A5—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	0.000112	0.0022	CbGpPWpGaD
Erlotinib—EGFR—DAP12 interactions—VAV3—hypothyroidism	0.00011	0.00217	CbGpPWpGaD
Erlotinib—EGFR—Fc epsilon receptor (FCERI) signaling—VAV3—hypothyroidism	0.00011	0.00217	CbGpPWpGaD
Erlotinib—JAK3—Hemostasis—VAV3—hypothyroidism	0.000109	0.00214	CbGpPWpGaD
Erlotinib—CYP1A1—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	0.000106	0.00208	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—CLTC—hypothyroidism	0.000104	0.00204	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—CLTC—hypothyroidism	0.000103	0.00202	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—TSHB—hypothyroidism	0.000102	0.002	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—TSHR—hypothyroidism	0.000102	0.002	CbGpPWpGaD
Erlotinib—ABCG2—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	9.76e-05	0.00192	CbGpPWpGaD
Erlotinib—CYP2C8—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	9.72e-05	0.00191	CbGpPWpGaD
Erlotinib—SLCO2B1—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	9.69e-05	0.0019	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—IYD—hypothyroidism	9.38e-05	0.00184	CbGpPWpGaD
Erlotinib—CYP3A5—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	9.1e-05	0.00179	CbGpPWpGaD
Erlotinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—AVP—hypothyroidism	9.09e-05	0.00179	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—TRH—hypothyroidism	8.97e-05	0.00176	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—IYD—hypothyroidism	8.75e-05	0.00172	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—CLTC—hypothyroidism	8.73e-05	0.00171	CbGpPWpGaD
Erlotinib—CYP1A1—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	8.59e-05	0.00169	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—SH2B3—hypothyroidism	8.12e-05	0.00159	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—TSHB—hypothyroidism	8e-05	0.00157	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—TSHR—hypothyroidism	8e-05	0.00157	CbGpPWpGaD
Erlotinib—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	7.98e-05	0.00157	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—ATP5O—hypothyroidism	7.97e-05	0.00157	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—IYD—hypothyroidism	7.96e-05	0.00156	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—VAV3—hypothyroidism	7.96e-05	0.00156	CbGpPWpGaD
Erlotinib—UGT1A1—Biological oxidations—POMC—hypothyroidism	7.95e-05	0.00156	CbGpPWpGaD
Erlotinib—CYP2C8—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	7.88e-05	0.00155	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CLTC—hypothyroidism	7.83e-05	0.00154	CbGpPWpGaD
Erlotinib—SLCO2B1—Transmembrane transport of small molecules—AVP—hypothyroidism	7.63e-05	0.0015	CbGpPWpGaD
Erlotinib—MKNK1—Disease—PRL—hypothyroidism	7.55e-05	0.00148	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—VAV3—hypothyroidism	7.51e-05	0.00148	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—TPO—hypothyroidism	7.5e-05	0.00147	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—IGF1—hypothyroidism	7.48e-05	0.00147	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—ATP5O—hypothyroidism	7.44e-05	0.00146	CbGpPWpGaD
Erlotinib—CYP1B1—Biological oxidations—POMC—hypothyroidism	7.41e-05	0.00146	CbGpPWpGaD
Erlotinib—ALB—Platelet degranulation—IGF1—hypothyroidism	7.38e-05	0.00145	CbGpPWpGaD
Erlotinib—ALB—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	7.27e-05	0.00143	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—SH2B3—hypothyroidism	7.13e-05	0.0014	CbGpPWpGaD
Erlotinib—ALB—Response to elevated platelet cytosolic Ca2+—IGF1—hypothyroidism	7.04e-05	0.00138	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—TPO—hypothyroidism	6.99e-05	0.00137	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—VAV3—hypothyroidism	6.88e-05	0.00135	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—VAV3—hypothyroidism	6.8e-05	0.00134	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—ATP5O—hypothyroidism	6.77e-05	0.00133	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TRH—hypothyroidism	6.77e-05	0.00133	CbGpPWpGaD
Erlotinib—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	6.76e-05	0.00133	CbGpPWpGaD
Erlotinib—JAK3—Hemostasis—IGF1—hypothyroidism	6.7e-05	0.00132	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—AVP—hypothyroidism	6.62e-05	0.0013	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	6.48e-05	0.00127	CbGpPWpGaD
Erlotinib—CYP2D6—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	6.47e-05	0.00127	CbGpPWpGaD
Erlotinib—EGFR—Focal Adhesion—IGF1—hypothyroidism	6.42e-05	0.00126	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—IGF1—hypothyroidism	6.39e-05	0.00125	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CLTC—hypothyroidism	6.38e-05	0.00125	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	6.37e-05	0.00125	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—TPO—hypothyroidism	6.36e-05	0.00125	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—VAV3—hypothyroidism	6.24e-05	0.00123	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CLTC—hypothyroidism	6.2e-05	0.00122	CbGpPWpGaD
Erlotinib—JAK3—Immune System—PRL—hypothyroidism	6.17e-05	0.00121	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TSHB—hypothyroidism	6.03e-05	0.00118	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TSHR—hypothyroidism	6.03e-05	0.00118	CbGpPWpGaD
Erlotinib—ALB—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	6.02e-05	0.00118	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—AVP—hypothyroidism	6.02e-05	0.00118	CbGpPWpGaD
Erlotinib—ALB—SLC-mediated transmembrane transport—SLC5A5—hypothyroidism	5.72e-05	0.00112	CbGpPWpGaD
Erlotinib—JAK3—Immune System—VAV3—hypothyroidism	5.71e-05	0.00112	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—IYD—hypothyroidism	5.7e-05	0.00112	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—VAV3—hypothyroidism	5.68e-05	0.00112	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—VAV3—hypothyroidism	5.57e-05	0.00109	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TRH—hypothyroidism	5.51e-05	0.00108	CbGpPWpGaD
Erlotinib—CYP1A2—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	5.48e-05	0.00108	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—IYD—hypothyroidism	5.39e-05	0.00106	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—SH2B3—hypothyroidism	5.37e-05	0.00106	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—VAV3—hypothyroidism	5.32e-05	0.00104	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CLTC—hypothyroidism	5.3e-05	0.00104	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—PRL—hypothyroidism	5.29e-05	0.00104	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	5.28e-05	0.00104	CbGpPWpGaD
Erlotinib—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	5.22e-05	0.00102	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—VAV3—hypothyroidism	5.01e-05	0.000985	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—TRH—hypothyroidism	5.01e-05	0.000984	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—IYD—hypothyroidism	4.94e-05	0.00097	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TSHB—hypothyroidism	4.92e-05	0.000965	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TSHR—hypothyroidism	4.92e-05	0.000965	CbGpPWpGaD
Erlotinib—ALB—Metabolism—IYD—hypothyroidism	4.91e-05	0.000964	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—VAV3—hypothyroidism	4.89e-05	0.000961	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—VAV3—hypothyroidism	4.85e-05	0.000953	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—ATP5O—hypothyroidism	4.85e-05	0.000952	CbGpPWpGaD
Erlotinib—CYP3A5—Biological oxidations—POMC—hypothyroidism	4.83e-05	0.000949	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—AVP—hypothyroidism	4.71e-05	0.000925	CbGpPWpGaD
Erlotinib—ABCG2—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	4.71e-05	0.000924	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ATP5O—hypothyroidism	4.58e-05	0.000899	CbGpPWpGaD
Erlotinib—CYP1A1—Biological oxidations—POMC—hypothyroidism	4.57e-05	0.000897	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—TPO—hypothyroidism	4.56e-05	0.000895	CbGpPWpGaD
Erlotinib—ALB—SLC-mediated transmembrane transport—AVP—hypothyroidism	4.5e-05	0.000884	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—TSHB—hypothyroidism	4.47e-05	0.000877	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—TSHR—hypothyroidism	4.47e-05	0.000877	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—POMC—hypothyroidism	4.4e-05	0.000865	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—SH2B3—hypothyroidism	4.38e-05	0.00086	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—TPO—hypothyroidism	4.31e-05	0.000846	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—IYD—hypothyroidism	4.3e-05	0.000845	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—VAV3—hypothyroidism	4.28e-05	0.000841	CbGpPWpGaD
Erlotinib—CYP3A4—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	4.23e-05	0.000831	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ATP5O—hypothyroidism	4.2e-05	0.000825	CbGpPWpGaD
Erlotinib—CYP2C8—Biological oxidations—POMC—hypothyroidism	4.19e-05	0.000822	CbGpPWpGaD
Erlotinib—ALB—Metabolism—ATP5O—hypothyroidism	4.17e-05	0.00082	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—IYD—hypothyroidism	4.05e-05	0.000796	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—POMC—hypothyroidism	4e-05	0.000785	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—SH2B3—hypothyroidism	3.99e-05	0.000785	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	3.99e-05	0.000783	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—PRL—hypothyroidism	3.99e-05	0.000783	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—TPO—hypothyroidism	3.95e-05	0.000775	CbGpPWpGaD
Erlotinib—ALB—Metabolism—TPO—hypothyroidism	3.93e-05	0.000771	CbGpPWpGaD
Erlotinib—ABCG2—Transmembrane transport of small molecules—AVP—hypothyroidism	3.71e-05	0.000728	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—VAV3—hypothyroidism	3.69e-05	0.000724	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ATP5O—hypothyroidism	3.66e-05	0.000718	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	3.66e-05	0.000718	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	3.64e-05	0.000714	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—AVP—hypothyroidism	3.55e-05	0.000698	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—TSHB—hypothyroidism	3.47e-05	0.000682	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ATP5O—hypothyroidism	3.45e-05	0.000677	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—TPO—hypothyroidism	3.44e-05	0.000675	CbGpPWpGaD
Erlotinib—CYP2D6—Biological oxidations—POMC—hypothyroidism	3.44e-05	0.000675	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—IYD—hypothyroidism	3.43e-05	0.000674	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—IGF1—hypothyroidism	3.43e-05	0.000674	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CLTC—hypothyroidism	3.42e-05	0.000672	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—IGF1—hypothyroidism	3.28e-05	0.000643	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—PRL—hypothyroidism	3.25e-05	0.000638	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—TPO—hypothyroidism	3.24e-05	0.000636	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—TSHB—hypothyroidism	3.24e-05	0.000636	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—hypothyroidism	3.23e-05	0.000633	CbGpPWpGaD
Erlotinib—ABL1—Immune System—PRL—hypothyroidism	3.16e-05	0.00062	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—POMC—hypothyroidism	3.13e-05	0.000615	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PIK3C2A—hypothyroidism	3.09e-05	0.000608	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—IGF1—hypothyroidism	3.01e-05	0.000592	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—VAV3—hypothyroidism	3.01e-05	0.000591	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TRH—hypothyroidism	2.96e-05	0.000581	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—TSHB—hypothyroidism	2.94e-05	0.000578	CbGpPWpGaD
Erlotinib—ABL1—Immune System—VAV3—hypothyroidism	2.92e-05	0.000574	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ATP5O—hypothyroidism	2.92e-05	0.000573	CbGpPWpGaD
Erlotinib—CYP1A2—Biological oxidations—POMC—hypothyroidism	2.91e-05	0.000572	CbGpPWpGaD
Erlotinib—ALB—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	2.9e-05	0.00057	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—AVP—hypothyroidism	2.9e-05	0.000569	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PIK3C2A—hypothyroidism	2.89e-05	0.000567	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	2.85e-05	0.000559	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—TPO—hypothyroidism	2.75e-05	0.000539	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—VAV3—hypothyroidism	2.74e-05	0.000538	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—VAV3—hypothyroidism	2.73e-05	0.000536	CbGpPWpGaD
Erlotinib—EGFR—Immune System—PRL—hypothyroidism	2.7e-05	0.00053	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—IYD—hypothyroidism	2.65e-05	0.000521	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TSHB—hypothyroidism	2.64e-05	0.000518	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TSHR—hypothyroidism	2.64e-05	0.000518	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—AVP—hypothyroidism	2.63e-05	0.000517	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PIK3C2A—hypothyroidism	2.62e-05	0.000515	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—SLC5A5—hypothyroidism	2.6e-05	0.00051	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	2.54e-05	0.0005	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	2.54e-05	0.0005	CbGpPWpGaD
Erlotinib—EGFR—Immune System—VAV3—hypothyroidism	2.5e-05	0.00049	CbGpPWpGaD
Erlotinib—EGFR—Disease—PRL—hypothyroidism	2.49e-05	0.000489	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—SLC5A5—hypothyroidism	2.42e-05	0.000476	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—POMC—hypothyroidism	2.36e-05	0.000464	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SH2B3—hypothyroidism	2.35e-05	0.000462	CbGpPWpGaD
Erlotinib—ALB—Transmembrane transport of small molecules—AVP—hypothyroidism	2.29e-05	0.000449	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—IGF1—hypothyroidism	2.27e-05	0.000446	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ATP5O—hypothyroidism	2.25e-05	0.000443	CbGpPWpGaD
Erlotinib—CYP3A4—Biological oxidations—POMC—hypothyroidism	2.25e-05	0.000441	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—SLC5A5—hypothyroidism	2.2e-05	0.000433	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—TPO—hypothyroidism	2.12e-05	0.000416	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—TSHB—hypothyroidism	2.11e-05	0.000414	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—AVP—hypothyroidism	2e-05	0.000393	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—TSHB—hypothyroidism	1.99e-05	0.000391	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—POMC—hypothyroidism	1.93e-05	0.000378	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3C2A—hypothyroidism	1.88e-05	0.000369	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IGF1—hypothyroidism	1.85e-05	0.000364	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—TSHB—hypothyroidism	1.83e-05	0.000359	CbGpPWpGaD
Erlotinib—ALB—Metabolism—TSHB—hypothyroidism	1.82e-05	0.000357	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3C2A—hypothyroidism	1.78e-05	0.000349	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	1.75e-05	0.000344	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—POMC—hypothyroidism	1.75e-05	0.000343	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PRL—hypothyroidism	1.74e-05	0.000343	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—IGF1—hypothyroidism	1.69e-05	0.000332	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3C2A—hypothyroidism	1.63e-05	0.00032	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3C2A—hypothyroidism	1.62e-05	0.000318	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—VAV3—hypothyroidism	1.61e-05	0.000317	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	1.61e-05	0.000316	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	1.6e-05	0.000314	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—TSHB—hypothyroidism	1.59e-05	0.000313	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—SLC5A5—hypothyroidism	1.58e-05	0.00031	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—AVP—hypothyroidism	1.55e-05	0.000305	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—TSHB—hypothyroidism	1.5e-05	0.000295	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—SLC5A5—hypothyroidism	1.49e-05	0.000293	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3C2A—hypothyroidism	1.42e-05	0.000279	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—SLC5A5—hypothyroidism	1.37e-05	0.000269	CbGpPWpGaD
Erlotinib—ALB—Metabolism—SLC5A5—hypothyroidism	1.36e-05	0.000267	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—POMC—hypothyroidism	1.36e-05	0.000267	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3C2A—hypothyroidism	1.34e-05	0.000263	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—TSHB—hypothyroidism	1.27e-05	0.00025	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—POMC—hypothyroidism	1.27e-05	0.000249	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—SLC5A5—hypothyroidism	1.19e-05	0.000234	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—POMC—hypothyroidism	1.15e-05	0.000227	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3C2A—hypothyroidism	1.13e-05	0.000222	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—SLC5A5—hypothyroidism	1.12e-05	0.000221	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	1.12e-05	0.00022	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—POMC—hypothyroidism	1.03e-05	0.000203	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IGF1—hypothyroidism	9.94e-06	0.000195	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—TSHB—hypothyroidism	9.81e-06	0.000193	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—SLC5A5—hypothyroidism	9.51e-06	0.000187	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3C2A—hypothyroidism	8.74e-06	0.000172	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—POMC—hypothyroidism	8.26e-06	0.000162	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—POMC—hypothyroidism	7.81e-06	0.000153	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SLC5A5—hypothyroidism	7.34e-06	0.000144	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—POMC—hypothyroidism	7.16e-06	0.000141	CbGpPWpGaD
Erlotinib—ALB—Metabolism—POMC—hypothyroidism	7.12e-06	0.00014	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—POMC—hypothyroidism	6.24e-06	0.000122	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—POMC—hypothyroidism	5.88e-06	0.000115	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—POMC—hypothyroidism	4.98e-06	9.78e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—POMC—hypothyroidism	3.84e-06	7.55e-05	CbGpPWpGaD
